Natrecor, Johnson & Johnson’s drug to treat decompensated congestive heart failure, has been linked to a higher risk of death than other standard, and much less expensive, treatments.
In May of 2005 the FDA (Federal Drug Administration) issued a Medwatch alert that US regulators had required new warnings on Natrecor. The new information focused on death rates from Natrecor use as compared to other treatments and the risks of kidney damage from Natrecor. Scios and the FDA sent the opinions of an expert panel on these subjects to health care professionals in July 2005.
On January 2, 2006 Johnson & Johnson’s Scios division sent the FDA reports of 2 deaths of patients who died within 30 days of treatment that had not been reported to the FDA when it made its labeling decision in 2005. The FDA must now reconsider the safety of Natrecor in light of these recent events.
Check out the following articles for more information about Natrecor, filing a Natrecor lawsuit and finding a Natrecor attorney: